Exicure Inc (NASDAQ:XCUR) — Market Cap & Net Worth
Market Cap & Net Worth: Exicure Inc (XCUR)
Exicure Inc (NASDAQ:XCUR) has a market capitalization of $10.20 Million ($10.20 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26967 globally and #5520 in its home market, demonstrating a -6.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Exicure Inc's stock price $1.60 by its total outstanding shares 6373937 (6.37 Million). See XCUR capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Exicure Inc Market Cap History: 2018 to 2026
Exicure Inc's market capitalization history from 2018 to 2026. Data shows change from $3.38 Billion to $10.20 Million (-49.94% CAGR).
Index Memberships
Exicure Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #764 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2490 of 3165 |
Weight: Exicure Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Exicure Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Exicure Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
174.26x
Exicure Inc's market cap is 174.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $3.38 Billion | $118.00K | -$22.41 Million | 28682.72x | N/A |
| 2019 | $2.73 Billion | $1.30 Million | -$26.30 Million | 2109.89x | N/A |
| 2020 | $1.69 Billion | $16.61 Million | -$24.67 Million | 101.86x | N/A |
| 2021 | $193.23 Million | $-483.00K | -$64.10 Million | -400.05x | N/A |
| 2022 | $36.65 Million | $28.83 Million | -$2.58 Million | 1.27x | N/A |
| 2024 | $87.13 Million | $500.00K | -$9.70 Million | 174.26x | N/A |
Competitor Companies of XCUR by Market Capitalization
Companies near Exicure Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Exicure Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Exicure Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Exicure Inc's market cap moved from $3.38 Billion to $ 10.20 Million, with a yearly change of -49.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.20 Million | -70.48% |
| 2025 | $34.55 Million | -60.35% |
| 2024 | $87.13 Million | +371.14% |
| 2023 | $18.49 Million | -49.54% |
| 2022 | $36.65 Million | -81.03% |
| 2021 | $193.23 Million | -88.58% |
| 2020 | $1.69 Billion | -38.11% |
| 2019 | $2.73 Billion | -19.21% |
| 2018 | $3.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Exicure Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.20 Million USD |
| MoneyControl | $10.20 Million USD |
| MarketWatch | $10.20 Million USD |
| marketcap.company | $10.20 Million USD |
| Reuters | $10.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood Ci… Read more